title: PharmGKB summary: very important pharmacogene information for CFTR.
authors.affiliation: Departments of aGenetics, Stanford School of Medicine bBioengineering, Stanford University, Stanford, California cDivision of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center dDepartment of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
authors.forename: Ellen M
authors.initials: EM
authors.lastname: McDonagh
authors.forename: John P
authors.initials: JP
authors.lastname: Clancy
authors.forename: Russ B
authors.initials: RB
authors.lastname: Altman
authors.forename: Teri E
authors.initials: TE
authors.lastname: Klein
mesh_terms: D000627:Aminophenols / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics* / Q000378:metabolism; D004359:Drug Therapy, Combination; D006801:Humans; D058990:Molecular Targeted Therapy; D020641:Polymorphism, Single Nucleotide / Q000187:drug effects; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000627:Aminophenols; C505032:CFTR protein, human; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor